9 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $50000 | -$46M | 0.0% | -94766.0% | -$24M | — | $25M |
| 2024 | $14000 | -$42M | 0.0% | -304535.7% | — | $15M | $21M |
| 2023 | $155000 | -$30M | 0.0% | -19187.7% | — | — | $36M |
| 2022 | $374000 | -$27M | 0.0% | -6938.8% | — | $15M | $52M |
| 2021 | $181000 | -$30M | 0.0% | -16106.6% | — | $15M | $75M |
| 2020 | $11000 | -$12M | 0.0% | -111163.6% | — | — | $22M |
| 2019 | — | -$8M | — | — | — | — | — |
| 2018 | $0 | -$12M | — | — | — | — | — |
| 2017 | $0 | -$831486 | — | — | — | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$5M | — | — | — | — | $21M |
| Dec '25 | $0 | -$5M | — | — | -$3M | — | $25M |
| Sep '25 | $0 | -$6M | — | — | -$6M | — | $28M |
| Jun '25 | $0 | -$24M | — | — | — | $15M | $33M |
| Mar '25 | $50000 | -$10M | 0.0% | -19810.0% | — | $15M | $19M |
| Dec '24 | $0 | -$9M | — | — | — | $15M | $21M |
| Sep '24 | $0 | -$12M | — | — | — | — | $34M |
| Jun '24 | $0 | -$10M | — | — | — | — | $31M |
| Mar '24 | $14000 | -$11M | 0.0% | -78692.9% | — | — | $26M |
| Dec '23 | $28000 | -$8M | 0.0% | -29925.0% | — | — | $36M |
| Sep '23 | $43000 | -$9M | 0.0% | -19832.6% | — | $13M | $42M |
| Jun '23 | $46000 | -$7M | 0.0% | -13937.0% | — | $15M | $48M |
| Mar '23 | $38000 | -$7M | 0.0% | -16902.6% | — | $15M | $51M |
| Dec '22 | $97000 | -$6M | 0.0% | -5816.5% | — | $15M | $52M |
| Sep '22 | $98000 | -$8M | 0.0% | -7594.9% | — | $15M | $57M |
| Jun '22 | $16000 | -$7M | 0.0% | -39925.0% | — | $15M | $61M |
| Mar '22 | $163000 | -$7M | 0.0% | -3974.2% | — | $15M | $67M |
| Dec '21 | $163000 | -$10M | 0.0% | -5539.9% | — | $15M | $75M |
| Sep '21 | $14000 | -$9M | 0.0% | -64435.7% | — | $15M | — |
| Jun '21 | $0 | -$7M | — | — | — | $14M | — |
How the market has priced INMB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Inmune Bio, Inc.'s revenue has grown 35.4% per year. These are computed facts, not advice.
As of FY2025, Inmune Bio, Inc. reported — of total debt against $25M of cash.
In FY2025, gross margin was —, operating margin -94766.0%, and net margin -92000.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.